Results 241 to 250 of about 16,055 (257)
Some of the next articles are maybe not open access.
Pharmaceutical cocrystals: walking the talk
Chemical Communications, 2016From Saridon to Entresto: the journey of pharmaceuticals from the first drug–drug combination of propyphenazone and pyrithyldione in 1937 (left) to the most recent monosodium sacubitril and disodium valsartan in 2015 (right).
Geetha, Bolla, Ashwini, Nangia
openaire +2 more sources
Cocrystal: A Review on the Design and Preparation of Pharmaceutical Cocrystals
Asian Journal of Research in Pharmaceutical Sciences, 2023The majority of the active pharmaceutical components have issues with poor solubility, bioavailability, chemical stability, and moisture absorption. Pharmaceutical crystals are a reliable way to change the aforementioned physicochemical properties of drugs without changing their pharmacological behaviour.
Tanmay Jit +4 more
openaire +1 more source
International Journal of Pharmaceutics, 2012
Cocrystals (CCs) used in the pharmaceutical industry are defined as complex crystals formed by reaction between an API and a cocrystal former (CCF); unlike salts, CCs do not show proton transfer. Recently, pharmaceutical CCs have been used to improve the drug-likeness of APIs, such as solubility and stability.
Katsuhiko, Yamamoto +2 more
openaire +2 more sources
Cocrystals (CCs) used in the pharmaceutical industry are defined as complex crystals formed by reaction between an API and a cocrystal former (CCF); unlike salts, CCs do not show proton transfer. Recently, pharmaceutical CCs have been used to improve the drug-likeness of APIs, such as solubility and stability.
Katsuhiko, Yamamoto +2 more
openaire +2 more sources
Advanced methodologies for cocrystal synthesis
Advanced Drug Delivery Reviews, 2017Pharmaceutical cocrystals are multicomponent systems composed of two or more molecules and held together by H-bonding. Currently, cocrystals provide exciting opportunities in the pharmaceutical industry for the development and manufacturing of new medicines by improving poor physical properties of Active Pharmaceutical Ingredients (APIs) such as ...
Dennis Douroumis +2 more
openaire +2 more sources
2017
The aim of this project is to improve cocrystal screening and solubility prediction methods.
openaire +1 more source
The aim of this project is to improve cocrystal screening and solubility prediction methods.
openaire +1 more source
2017
The aim of this project is to improve solubility and dissolution rate of active pharmaceutical ingrednient via cocrystallization.
openaire +1 more source
The aim of this project is to improve solubility and dissolution rate of active pharmaceutical ingrednient via cocrystallization.
openaire +1 more source
A melt castable energetic cocrystal
Chemical Communications, 2017Cocrystallization leads to melt-state stabilization of the thermally unstable energetic 4-amino-3,5-dinitropyrazole, allowing for production of a melt castable cocrystalline explosive.
Jonathan C. Bennion +2 more
openaire +2 more sources
Cocrystal formulations: A case study of topical formulations consisting of ferulic acid cocrystals
European Journal of Pharmaceutics and Biopharmaceutics, 2020Renaissance of cocrystals as alternative solid forms for fine-tuning physicochemical properties of active pharmaceutical ingredients (APIs) has paved way for development of marketable cocrystals. The current literature reveals established strategies for the design, synthesis and characterization of cocrystals.
Srinivasulu, Aitipamula, Surajit, Das
openaire +2 more sources
Chrysin cocrystals: Characterization and evaluation
Journal of Pharmaceutical and Biomedical Analysis, 2017Solvent free mechanochemical approach is utilized to synthesise new cocrystals of chrysin using supramolecular chemistry based upon reliable synthons. Chrysin, a flavone nutraceutical with wide range of beneficial effects has critically low bioavailability on account of its poor aqueous solubility and consequently poor absorption from the ...
Renu, Chadha +4 more
openaire +2 more sources
Furosemide Cocrystals with Pyridines: An Interesting Case of Color Cocrystal Polymorphism
Crystal Growth & Design, 2015Furosemide (FS), a loop diuretic drug commonly used for the treatment of hypertension and edema, exhibited color cocrystal polymorphism with coformer 4,4′-bipyridine (4BPY) in the stoichiometry 2:1, albeit both the API and the cocrystal former are colorless.
Ekta Sangtani +6 more
openaire +1 more source